Nanochemtech (091970) has 4 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩307M ($213K) in reported transaction value. The earliest filing StockDrifts holds for Nanochemtech is dated 2024-07-29; the most recent is 2026-06-17. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +28.27%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | BUY | Market Buy | 김태수 Kim Tae-soo | moving | 3.1K | ₩3,225 | +10.7% | ₩10M ($7K) |
| 2026-06-12 | SELL | 전환등 | 신해용 Shin Hae-yong | Internal director | -17.1K | ₩3,025 | -18.0% | ₩52M ($36K) |
| 2026-05-05 | SELL | 주식병합 | 트리니티에쿼티 Trinity Equity | - | -6.9M | ₩3,785 | -12.7% | ₩25.9B ($18.0M) |
| 2026-05-05 | SELL | 행사가액조정 | 트리니티에쿼티 Trinity Equity | - | -3.8M | ₩3,785 | -12.7% | ₩14.5B ($10.1M) |
| 2026-05-05 | SELL | 주식병합 | 이상규 Lee Sang-gyu | Chairman | -1.9M | ₩3,785 | -12.7% | ₩7.2B ($5.0M) |
| 2026-05-05 | SELL | 주식병합 | 디비인베스트먼트 DB Investment | - | -411.7K | ₩3,785 | -12.7% | ₩1.6B ($1.1M) |
| 2026-05-05 | SELL | 행사가액조정 | 신해용 Shin Hae-yong | Internal director | -68.4K | ₩3,785 | -12.7% | ₩259M ($180K) |
| 2026-05-05 | SELL | 주식병합 | 신해용 Shin Hae-yong | Internal director | -91.1K | ₩3,785 | -12.7% | ₩345M ($240K) |
| 2026-05-05 | SELL | 주식병합 | 소병적 petit pathological | Managing Director | -41.0K | ₩3,785 | -12.7% | ₩155M ($108K) |
| 2026-03-05 | BUY | Market Buy | 디비인베스트먼트 DB Investment | - | 31.2K | ₩480 | +50.0% | ₩15M ($10K) |
| 2026-03-03 | BUY | Market Buy | 디비인베스트먼트 DB Investment | - | 53.8K | ₩555 | +29.7% | ₩30M ($21K) |
| 2026-02-27 | BUY | Market Buy | 디비인베스트먼트 DB Investment | - | 429.6K | ₩587 | +22.7% | ₩252M ($175K) |
| 2025-11-04 | SELL | 전환등 | 소병적 petit pathological | Managing Director | -51.3K | ₩847 | +15.0% | ₩43M ($30K) |
| 2025-11-04 | BUY | 전환사채의권리행사 | 소병적 petit pathological | Managing Director | 51.3K | ₩847 | -15.0% | ₩43M ($30K) |
| 2024-07-29 | BUY | CB인수 | 오희갑 Oh Hee-gap | moving | 51.3K | ₩571 | +26.1% | ₩29M ($20K) |
| 2024-07-29 | BUY | CB인수 | 신해용 Shin Hae-yong | Internal director | 85.5K | ₩571 | +26.1% | ₩49M ($34K) |
| 2024-07-29 | BUY | CB인수 | 소병적 petit pathological | Managing Director | 51.3K | ₩571 | +26.1% | ₩29M ($20K) |
| 2024-07-29 | BUY | CB인수 | 트리니티에쿼티 Trinity Equity | - | 4.8M | ₩571 | +26.1% | ₩2.7B ($1.9M) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Nanochemtech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.